Corrigendum to “A comparison of the efficacy of trastuzumab deruxtecan in advanced HER2-positive breast cancer: active brain metastasis versus progressive extracranial disease alone”: [ESMO Open 8 (2023) 102033] (ESMO Open (2023) 8(6), (S2059702923012747), (10.1016/j.esmoop.2023.102033))

Collapse authors list.
Pearson, J, Khan, A, Bhogal, T ORCID: 0000-0003-3297-9957, Wong, H, Law, A, Mills, S, Santamaria, N, Bishop, J, Cliff, J, Errington, D et al (show 10 more authors) , Hall, A, Hart, C, Malik, Z, Sripadam, R, Innes, H, Flint, H, Langton, G, Ahmed, E, Jackson, R ORCID: 0000-0002-7814-5088 and Palmieri, C ORCID: 0000-0001-9496-2718 (2024) Corrigendum to “A comparison of the efficacy of trastuzumab deruxtecan in advanced HER2-positive breast cancer: active brain metastasis versus progressive extracranial disease alone”: [ESMO Open 8 (2023) 102033] (ESMO Open (2023) 8(6), (S2059702923012747), (10.1016/j.esmoop.2023.102033)) ESMO Open, 9 (6). 103621-. ISSN 2059-7029, 2059-7029

Text Corrigendum to A comparison of the efficacy of trastuzumab deruxtecan in advanced HER2-positive breast cancer active brain m.pdf - Open Access published version Download (150kB) | Preview

Abstract

The authors regret that in the original report some figures from previous studies are incorrectly given. The correct figures are as follows For "The reported rate of pneumonitis in the most comparable trial population namely DESTINY-Breast02 was 6% (25) with two grade 5 deaths (<1%).", read “The reported rate of pneumonitis in the most comparable trial population namely DESTINY-Breast02 was 10% (42) with two grade 5 deaths (<1%).” For "This intracranial therapeutic effect appears not to be limited to T-DXd, a pre-specified subgroup analysis of HER2CLIMB found in patients receiving tucatinib; the median OS was 21.6 months (95% CI 18.1-28.5 months) for those with BM versus 24.7 months (95% CI 21.6-28.9 months) for those without BM.", read “This intracranial therapeutic effect appears not to be limited to T-DXd, a pre-specified subgroup analysis of HER2CLIMB found in patients receiving tucatinib; the median OS was 21.6 months (95% CI 18.1-28.5 months) for those with BM versus 24.7 months (95% CI 21.6-28.9 months) for those with and without BM.” The authors would like to apologise for any inconvenience caused.

Item Type:	Article
Uncontrolled Keywords:	32 Biomedical and Clinical Sciences, 3211 Oncology and Carcinogenesis, Cancer, Breast Cancer, Neurosciences, Women's Health, Cancer
Divisions:	Faculty of Health & Life Sciences Faculty of Health & Life Sciences > Inst. Life Courses & Medical Sciences Faculty of Health & Life Sciences > Inst. Life Courses & Medical Sciences > School of Medicine Faculty of Health & Life Sciences > Inst. Population Health Faculty of Health & Life Sciences > Inst. Systems, Molec & Integrative Biology > Inst. Systems, Molec & Integrative Biology
Depositing User:	Symplectic Admin
Date Deposited:	27 Jan 2025 08:32
Last Modified:	23 Jan 2026 20:07
DOI:	10.1016/j.esmoop.2024.103621
Related Websites:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3189888
Disclaimer:	The University of Liverpool is not responsible for content contained on other websites from links within repository metadata. Please contact us if you notice anything that appears incorrect or inappropriate.